NCT06189170 is a EARLY_PHASE1 clinical trial of KP405 in Safety Issues, sponsored by Kariya Pharmaceuticals.

Who is sponsoring NCT06189170?

NCT06189170 is sponsored by Kariya Pharmaceuticals.

What drugs are being tested in NCT06189170?

Interventions in NCT06189170: KP405, Placebo.

What condition does NCT06189170 study?

NCT06189170 studies Safety Issues, Tolerance.

Is NCT06189170 still recruiting?

NCT06189170 is currently recruiting now. Last updated 7 March 2025.

Last reviewed 2025-03-07 · How we verify

NCT06189170

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients

Recruiting now EARLY_PHASE1 Last updated 7 March 2025

What this trial tests

EARLY_PHASE1 trial testing KP405 in Safety Issues in 88 participants. Currently enrolling.

Timeline

1 August 2024

Primary endpoint
31 December 2025

31 March 2026

Quick facts

Lead sponsor	Kariya Pharmaceuticals
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	88
Start date	1 August 2024
Primary completion	31 December 2025
Estimated completion	31 March 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

KP405 — full drug profile →
Placebo

Conditions studied

Safety Issues — all drugs for Safety Issues →
Tolerance — all drugs for Tolerance →

Sponsor

Kariya Pharmaceuticals — full company profile →

Who can join

Adults 18 to 80, any sex, with Safety Issues or Tolerance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Kopp KO, Glotfelty EJ, Li Y, Lahiri DK, et al · · 2024 · cited 14× · PMID 38762101 · DOI 10.1016/j.arr.2024.102343

Verify or expand the search:

Other recruiting trials for Safety Issues

Currently open trials in the same condition.

NCT06485141 — BeSMART Secure Storage Counseling in the Inpatient Setting · NA · recruiting
NCT06494527 — A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults · Phase 1 · active not recruiting
NCT06509490 — NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors · NA · recruiting
NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
NCT06383377 — Evaluation of Performance, Safety and Benefit of the Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investi · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06189170 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kariya Pharmaceuticals
Last refreshed: 7 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06189170.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing